Zafgen Pockets $33M To Take Obesity Drug Through Next Big Step in Clinical Trials

7/7/11Follow @arleneweintraub

(Page 2 of 2)

to attend the public sessions that the agency held before handing down its rulings. “We not only paid close attention to what was said, but also to the body language of the regulators,” Hughes recalls. “It’s been a really educational year for us.”

The key takeaway, Hughes says, is that the FDA is not going to support any drug that’s aimed at the general population of overweight individuals unless, he says, “it’s incredibly effective or unbelievably safe.” All three of the treatments were only moderately effective and the FDA had safety concerns about all of them, Hughes points out.

Unlike those companies, Zafgen is designing its treatment only for a subset of patients who are severely obese, meaning they are so overweight that their health is in serious danger, and they would be prime candidates for bariatric surgery. That means the drug won’t be targeted at millions of people who merely need to shed a few pounds.

Even though Zafgen hasn’t yet advanced to the final stage of clinical development, Hughes says Zafgen is already thinking about its Risk Evaluation and Mitigation Strategy (REMS). These are plans that the FDA often requires drugmakers to put in place to reduce the chances of a new drug being improperly used in the marketplace. The REMS would establish registries of physicians, patients, and maybe even pharmacies, so the company can keep tabs on who’s taking the drug, Hughes says. He hopes that the fact that ZGN-433 has to be injected will add an additional barrier against misuse by people who aren’t ideal candidates for such a potent weight-loss drug.

Zafgen’s obesity program is unique in that the company started developing ZGN-433 before it could fully define how it works. Zafgen’s scientists originally believed MetAP2 inhibitors would cut off the blood supply to fat tissue, in turn promoting weight loss. But as they scrutinized the compound, it became clear to them that what it was really doing was changing the way the body metabolizes fat.

Hughes explains that when people reach the state of severe obesity, their liver overproduces fat, and the adipose tissue hordes that fat rather than releasing it. It’s a problem that exercise and dieting can’t fix. Zafgen’s drug reduces the over-production of fat in the liver, and stimulates the body to release the fat and transform it into an energy source, Hughes says.

Zafgen now has plenty of capital to take the drug through Phase 2 and beyond, if necessary, Hughes says. He says he’s open to forming a partnership with a Big Pharma company to take the drug further. And despite the recent negative FDA rulings in the obesity space, “there’s a lot of interest from pharma in our program,” Hughes says. “Obesity remains one of the largest unmet medical needs. The perception is that there is definitely a market there.”

Single Page Currently on Page: 1 2 previous page

By posting a comment, you agree to our terms and conditions.

  • Saumitra

    Excellent positioning by Zafgen.If you exaggerate the claims by 1000X, it would be like if these people don’t take our drug they will die of Obesity. They learnt from Vivus / Orexigen debacle and best part being strategizing for REMS so ‘early’ in development stage. If they come up with some Pharmacoeconomics figures comparing their drug costs with that of Bariatric surgery and risk of patients reverting to their original lifestyle they would have a strong case of approval.

  • Zoom

    Very good news indeed.

  • Pingback: A perfect example of regulatory risk… « biotechtranslated